Steminent Biotherapeutics Inc. (TPEX:7729)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
83.70
+0.50 (0.60%)
Jun 18, 2026, 2:59 PM CST
Market Cap5.58B +344.7%
Revenue (ttm)n/a
Net Income-174.04M
EPS-2.95
Shares Out 66.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume221,818
Open81.60
Previous Close83.20
Day's Range81.60 - 84.10
52-Week Range19.80 - 95.60
Beta0.18
Analystsn/a
Price Targetn/a
Earnings DateJun 24, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7729
Full Company Profile

Financial Performance

Financial Statements